Everything below concerns TB-500. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-02. Numbers and descriptions here follow the published literature rather than marketing material.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
| Property | Value | Notes |
|---|---|---|
| Reconstitution solvent | Sterile water or aqueous buffer | Aseptic technique recommended |
| Post-reconstitution storage | 2–8 °C short term; frozen for longer periods | Avoid repeated freeze-thaw cycles |
| Typical purity assay | Reversed-phase HPLC | Peak area used to estimate purity |
| Identity confirmation | Mass measurement | Compares observed value with expected mass |
| Main degradation routes | Hydrolysis and oxidation | Accelerated by heat and extreme pH |
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
She collaborated with the company again in February 2025, to promote the "Cherry Crush Zero Sugar" flavour, in which she and Jedward attempted a Guinness World Record to see how many post-it notes they could attach to her within a minute. The attempt, which was overseen by an adjudicator, saw them attach 30, failing to break the record of 70.
== History == Around 1900, surgeons tried injecting paraffin into the lips without success. Liquid silicone was used for lip augmentation, starting in the early 1960s but was abandoned thirty years later due to fears about the effects of silicone on general health and long term aesthetic outcome. In about 1980, injectable bovine collagen was introduced to the cosmetic surgery market and became the standard against which other injectable fillers were measured. However, that collagen does not last very long and requires an allergy test, causing the patient to wait at least three weeks before another appointment, after which more waiting is required to see cosmetic results.
=== Russia === Russia has a plan for increasing its fleet of fast breeder reactors significantly. A BN-800 reactor (800 MWe) at Beloyarsk was completed in 2012, succeeding a smaller BN-600. It reached its full power production in 2016. Plans for the construction of a larger BN-1200 reactor (1,200 MWe) was scheduled for completion in 2018, with two additional BN-1200 reactors built by the end of 2030. However, in 2015 Rosenergoatom postponed construction indefinitely to allow fuel design to be improved after more experience of operating the BN-800 reactor, and among cost concerns. In January 2026, Rosatom reported that preparations had begun for Beloyarsk Unit 5, using the BN-1200M sodium-cooled fast reactor. Construction of the lead-cooled BREST-OD-300 reactor at the Siberian Chemical Combine in Seversk began in June 2021. The BREST (Russian: bystry reaktor so svintsovym teplonositelem, English: fast reactor with lead coolant) design is seen as a successor to the BN series and the 300 MWe unit at the SCC could be the forerunner to a 1,200 MWe version for wide deployment as a commercial power generation unit. The development program is as part of an Advanced Nuclear Technologies Federal Program 2010–2020 that seeks to exploit fast reactors for uranium efficiency while 'burning' radioactive substances that would otherwise be disposed of as waste. Its core would measure about 2.3 metres in diameter by 1.1 metres in height and contain 16 tonnes of fuel. The unit would be refuelled every year, with each fuel element spending five years in total within the core.
== Business == George Batten (1854–1918), advertising executive whose firm was part of the merger that created what is now BBDO Clarence Birdseye (1886–1956), inventor, entrepreneur and naturalist who is considered to be the founder of the modern frozen food industry John C. Bogle (1929–2019), founder and CEO of The Vanguard Group, a pioneer in financial investments John J. Cali (1918–2014), real estate developer Israel Crane (1774–1858), merchant J. Clydesdale Cushman (1887–1955), businessman who co-founded the real estate firm Cushman & Wakefield in 1917 Allen B. DuMont (1901–1965), television pioneer and inventor who created the DuMont Television Network Stephen Glasser (1943–2022), American publisher who founded the Legal Times Floyd Hall (born 1935), CEO of Kmart Charles B. Johnson (born 1933), businessman Ken Kurson (born 1968), political consultant, writer and journalist, who was editor-in-chief of The New York Observer between 2013 and 2017 Geraldine Laybourne (born 1947), former TV executive and entrepreneur, co-founder of Nickelodeon and Oxygen cable networks Benjamin Moore (1905–1917), co-founder with his brother Robert of Benjamin Moore & Co, in Brooklyn in 1883; lived in Upper Montclair Guy T. Viskniskki (1876–1949), newspaper editor and news executive who founded the World War I edition of the Stars and Stripes newspaper while serving as a U.S. Army officer in France with the American Expeditionary Force Bernard Wakefield (c. 1883–1967), British-American executive who co-founded the real estate firm Cushman & Wakefield in 1917
On 7 January 2026, US senator Ruben Gallego introduced a resolution in the US senate to block Trump from invading Greenland. A few days later, Democratic and Republican senators introduced the bipartisan No Funds for NATO Invasion Act, which prohibits the use of federal funds for the invasion of any NATO member state or NATO-protected territory, as well as the bipartisan NATO Unity Protection Act to "prohibit the use of US Department of Defense or Department of State funds to blockade, occupy, annex or otherwise assert control over the sovereign territory of a NATO member state without that ally's consent or authorization from the North Atlantic Council", introduced by Republican senator Lisa Murkowski and Democratic senator Jeanne Shaheen. According to Murkowski, the Act seeks to stop Trump's threats against Greenland. Timothy Broglio, the Archbishop for the Military Services, USA, and former president of the United States Conference of Catholic Bishops, said Trump's actions tarnish the image of the US and that it would be morally acceptable for US soldiers to disobey "morally questionable" orders to attack Greenland. Former Trump spokesperson Sarah Matthews said Trump's Greenland threats were "the most mentally ill, deranged thing" he had done.
Sources: en.wikipedia.org
A majority of macrophages are stationed at strategic points where microbial invasion or accumulation of foreign particles is likely to occur. These cells together as a group are known as the mononuclear phagocyte system and were previously known as the reticuloendothelial system. Each type of macrophage, determined by its location, has a specific name:
=== Organic acid technology === Most modern cars are built with organic acid technology (OAT) antifreeze (e.g., DEX-COOL), or with a hybrid organic acid technology (HOAT) formulation (e.g., Zerex G-05), both of which are claimed to have an extended service life of five years or 240,000 km (150,000 mi). DEX-COOL specifically has caused controversy. Litigation has linked it with intake manifold gasket failures in General Motors' (GM's) 3.1L and 3.4L engines, and with other failures in 3.8L and 4.3L engines. One of the anti-corrosion components presented as sodium or potassium 2-ethylhexanoate and ethylhexanoic acid is incompatible with nylon 6,6 and silicone rubber, and is a known plasticizer. Class action lawsuits were registered in several states of the US, and in Canada, to address some of these claims. The first of these to reach a decision was in Missouri, where a settlement was announced early in December 2007. Late in March 2008, GM agreed to compensate complainants in the remaining 49 states. GM (Motors Liquidation Company) filed for bankruptcy in 2009, which tied up the outstanding claims until a court determines who gets paid. According to the DEX-COOL manufacturer, "mixing a 'green' [non-OAT] coolant with DEX-COOL reduces the batch's change interval to 2 years or 50,000 km (30,000 mi), but will otherwise cause no damage to the engine". DEX-COOL antifreeze uses two inhibitors: sebacate and 2-EHA (2-ethylhexanoic acid), the latter which works well with the hard water found in the United States, but is a plasticizer that can cause gaskets to leak.
Clayton (1956), fiction writer, novelist Robert Silverberg (1956), science fiction writer, recipient of the Damon Knight Memorial Grand Master Award in 2004 Paul Zweig (1956), poet, memoirist, 1976 Guggenheim Fellow George Bellak (1957), television writer Richard P. Brickner (1957), writer, 1983 Guggenheim Fellow Raymond Federman (1957), French–American novelist and academic; author, Double or Northing Lawrence Shainberg (1958), writer of Zen Buddhism Jerome Charyn (1959), novelist Jay Neugeboren (1959), novelist, essayist, short story writer Robert T.
Red blood cell autoantibodies tend to be specific for red cell antigens of high frequency within the population. An antibody elution can aid in the identification of clinically significant alloantibodies when autoantibodies interfere with the antibody identification process.
Sources: en.wikipedia.org
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.
There is no broadly accepted figure for TB-500. Laboratory practice is short-term storage at 2–8 °C with longer-term aliquots frozen, and degradation is expected to increase with time and temperature. Users typically rely on their own stability checks rather than published data.
Mass measurement provides the clearest confirmation by matching an observed value to the expected one. Reversed-phase chromatography adds a purity estimate through peak integration. Combining both is standard because neither alone establishes identity and purity together.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.